{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-26-000057","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.015266+00:00","generated_at":"2026-05-14T21:24:50.549064+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Halozyme stockholders elect directors, approve say-on-pay, ratify auditor","bullets":["Directors Connaughton and Posard elected with 89.1M and 82.7M votes for, respectively.","Advisory vote on executive compensation approved: 84.7M for, 9.3M against.","Ratification of Ernst & Young as FY2026 auditor passed with 103.2M votes for.","Over 104.1M of 118.5M outstanding shares were represented at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-26-000057","json":"https://secwatch.observer/filing/0001159036-26-000057.json","markdown":"https://secwatch.observer/filing/0001159036-26-000057.md","text":"https://secwatch.observer/filing/0001159036-26-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000057/0001159036-26-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000057/halo-20260505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:24:50.549064+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3e55e38ec321cc4d7b0e3b3eeb4cde3aae13cc8e","claim":"HALOZYME THERAPEUTICS, INC. shareholders approved Ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-05 meeting.","evidence_excerpt":"Proposal 3: The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows: Votes For Votes Against Abstain Broker Non-Votes 103,197,579 849,433 91,232 --- The foregoing proposal was approved.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000057/0001159036-26-000057-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-05"}],"fact_type":"shareholder_vote"},{"claim_id":"81ee7d127e730c5f33c8b2f096b86dad889081b5","claim":"HALOZYME THERAPEUTICS, INC. shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2026-05-05 meeting.","evidence_excerpt":"Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows: Votes For Votes Against Abstain Broker Non-Votes 84,682,518 9,311,426 255,081 9,889,219 The foregoing proposal was approved.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000057/0001159036-26-000057-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-05"}],"fact_type":"shareholder_vote"},{"claim_id":"ce6546d9cc0d6d77e7d66bc062620b60a66938bc","claim":"HALOZYME THERAPEUTICS, INC. shareholders approved Election of two Class I directors to hold office for a three-year term expiring at the 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified at the 2026-05-05 meeting.","evidence_excerpt":"Proposal 1 : Election of two Class I directors to hold office for a three-year term expiring at the 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified: Names Votes For Votes Against Abstain Broker Non-Votes Bernadette Connaughton 89,053,734 5,068,160 127,131 9,889,219 Matthew L. Posard 82,739,433 10,236,878 1,272,714 9,889,219 Each of the foregoing candidates was elected and each received affirmative votes from more than a majority of the outstanding shares.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000057/0001159036-26-000057-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-05"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}